Blue Goat CyberBlue Goat CyberSMMedical Device Cybersecurity
    K
    Blog · FDA

    Modular PMA Submission: What MedTech Teams Need to Know (2026)

    Modular PMA Submission explained for medical device manufacturers, definition, FDA context, and what teams must document for 2026 submissions.

    Abstract network of interconnected medical device components symbolizing modular PMA submission and FDA clearance
    On this page
    Christian Espinosa, Founder & CEO at Blue Goat Cyber

    By Christian Espinosa, MBA, CISSP

    Founder & CEO · Blue Goat Cyber

    Published: November 10, 2024 · Last reviewed: May 1, 2026

    Key Takeaways

    • Divided into distinct sections for submission.
    • Enables continuous dialogue with the FDA.
    • Offers flexibility in the submission timeline.
    • Enhances risk management for complex devices.
    • Can improve efficiency and resource allocation.
    • Aims for quicker approval for new technologies.

    Part of our FDA 2026 medical device cybersecurity submission series. For the full overview, start with FDA Cybersecurity Requirements for Medical Devices (2026).

    Direct Answer

    Modular PMA Submission is a concept every medical device team should understand before an FDA submission. Here's what it means, why it matters in 2026, and how to document it.

    The Modular Premarket Approval (PMA) Submission is essential for medical device manufacturers seeking FDA clearance. This method breaks down the traditional submission process into manageable parts, promotes efficiency, and encourages a more interactive approach with the FDA. But what exactly does it entail? Let’s dive in.

    Why this matters

    The modular PMA submission method is crucial for efficiently introducing innovative, yet secure, medical devices to market. For manufacturers, it streamlines the regulatory pathway by allowing iterative feedback from the FDA, reducing the risk of a complete submission rejection. This approach is particularly relevant for devices with integrated software and connectivity, where cybersecurity is a critical component.

    The FDA's "Cybersecurity in Medical Devices" Final Guidance, dated February 3, 2026, emphasizes the need for well-documented cybersecurity controls throughout the device lifecycle. A Modular PMA can facilitate demonstrating adherence to standards such as IEC 81001-5-1 for health IT security and ISO 14971 for risk management, by allowing manufacturers to address these complex sections in dedicated modules. By tackling cybersecurity and other multifaceted requirements in phases, manufacturers can ensure that device safety and efficacy are reviewed, reducing potential post-market issues and recalls. This phased approach builds earlier identification and mitigation of risks, ultimately benefiting patient safety and healthcare system integrity.

    Understanding the Basics of a Modular PMA Submission

    A Modular PMA Submission allows developers to submit their application in discrete sections or modules. This method offers flexibility. Instead of submitting a complete package at once, companies can provide data progressively, improving the chances of successful approval for complex devices.

    Definition of a Modular PMA Submission

    A Modular PMA Submission is a structured way to present a medical device for FDA clearance. The submission is divided into distinct components, allowing smaller data portions to be submitted as they become available. This isn’t just a linear journey; it’s more like climbing a mountain, module by module. Each module can cover different aspects of the device, such as design, manufacturing processes, or clinical data, allowing for a more thorough and organized review process. This modular approach streamlines the submission and helps maintain clear communication with the FDA, as feedback can be incorporated into subsequent modules.

    Importance of a Modular PMA Submission

    Why is this approach significant? Think of it as a safety use for manufacturers. It mitigates risks associated with the lengthy approval process. Manufacturers can address potential issues in earlier modules rather than facing an all-or-nothing scenario. This method is a game-changer in navigating the often turbulent waters of medical device regulations.

    Additionally, it allows companies to adapt to evolving regulatory requirements and incorporate new findings or technological changes without restarting the entire submission process. By breaking down the submission into manageable parts, companies can allocate resources more effectively, ensuring that each module receives the attention it deserves, ultimately leading to a more and compliant product.

    Components of a Modular PMA Submission

    A Modular PMA Submission consists of several key components, each critical in the approval process. Let’s explore these modules in depth.

    Preclinical Module

    The Preclinical Module is the foundation of the submission. It includes all non-clinical data regarding the device’s safety and effectiveness. This may involve animal studies, testing protocols, and results demonstrating the device’s behavior before it’s tested on humans. The data gathered here must be and well-documented, as it sets the stage for subsequent modules.

    The preclinical phase often includes a thorough risk assessment, identifying potential hazards associated with the device, and outlining mitigation strategies. This proactive approach strengthens the submission and demonstrates a commitment to patient safety from the outset.

    Manufacturing Module

    Next is the Manufacturing Module. This section details how the device is produced. Manufacturers must provide information about their facilities, quality control processes, and equipment used in production. The FDA wants to see that you can consistently produce your device and meet all safety standards. A recipe without proper ingredients isn’t going to yield a cake!

    This module may also require a description of the supply chain management practices in place, ensuring that all materials sourced are of high quality and that contingency plans are in place for potential disruptions. Transparency in manufacturing processes not only builds trust with regulatory bodies but also enhances the overall credibility of the device.

    Clinical Module

    Finally, the Clinical Module spotlights human data. This is where the rubber meets the road; clinical trial data illustrates how the device performs in real-world settings. Details such as study design, statistical analysis, and patient outcomes are scrutinized here. It’s akin to sharing your final exam results-you better be prepared for questions!

    This module often includes post-market surveillance plans, outlining how the manufacturer intends to monitor the device’s performance once it is on the market. This ongoing commitment to safety and efficacy can significantly influence the FDA’s perception of the device’s overall risk-benefit profile, making it a vital aspect of the submission process.

    The Process of a Modular PMA Submission

    The journey through a Modular PMA Submission is both structured and critical. Following a systematic process can save time and resources. Let’s navigate through each step.

    Preparing for a Modular PMA Submission

    Preparation is everything. It’s not just about gathering data; it’s about strategic planning. Manufacturers must outline their submission roadmap and gather all necessary materials. Engaging with regulatory experts during this phase can provide insights and help avoid pitfalls. It’s like having a compass before setting off on a journey!

    Manufacturers should conduct a thorough risk assessment to identify potential challenges that may arise during the submission process. This proactive approach enables teams to devise contingency plans, ensuring they are well-equipped to address unforeseen issues.

    Assembling a cross-functional team that includes members from regulatory affairs, clinical, and quality assurance can build a collaborative environment, enhance the quality of the submission, and ensure that all perspectives are considered. This foundational work sets the stage for a smoother submission process, ultimately increasing the likelihood of a successful outcome.

    Submitting the Modules

    Once prepared, it’s time to submit those modules. Each submission is subject to review. Companies can submit each module as completed, remaining engaged with the FDA throughout the process. This is essential for maintaining regulatory momentum. Consider it a relay race, where passing the baton at the right time can lead to success.

    Effective communication with the FDA during this phase is crucial. Manufacturers should be prepared to provide additional context or clarification regarding their submissions, which can expedite the review process. Utilizing tools such as submission tracking systems can help keep all stakeholders informed about the status of each module, ensuring that everyone is aligned and aware of any upcoming deadlines or required actions. This level of diligence demonstrates a commitment to regulatory compliance and builds a positive relationship with the FDA, which can be beneficial for future submissions.

    Review and Approval Process

    After submission, the review process begins. The FDA assesses each module’s merits and looks at how they connect. This stage may involve back-and-forth communication. It’s an opportunity for clarification and further data requests. The process can feel like a tug of war; patience and perseverance are crucial.

    During this review phase, manufacturers need to remain responsive and organized. Keeping detailed records of all communications with the FDA can help streamline the process and ensure no critical information is overlooked. Additionally, manufacturers should be prepared for potential advisory committee meetings, where they may need to present their data and address questions from experts in the field. This engagement not only provides an opportunity to clarify any concerns but also allows manufacturers to showcase the robustness of their data and the safety and efficacy of their products. By approaching this stage with transparency and readiness, companies can significantly enhance their chances of a favorable review outcome.

    Benefits of a Modular PMA Submission

    The Modular PMA Submission isn’t just another piece of paperwork; it offers several advantages that can’t be overlooked. Companies often reap substantial rewards from this approach.

    Flexibility and Efficiency

    See also: Breakthrough Device Designation and Cybersecurity, FDA Penetration Testing Requirements, and Letter to File vs New 510(k).

    One of the most significant benefits is flexibility. This method allows manufacturers to work at their own pace. They are not tethered to the rigid timeline of traditional submissions. As a result, risks are lowered, and workflows become more efficient. It’s like driving a car with cruise control-you can relax while keeping your eyes on the road. This flexibility also extends to the ability to prioritize different components of the submission, allowing companies to focus on the most critical aspects first, which can lead to quicker approvals for essential technologies.

    Continuous Interaction with the FDA

    Another major perk is the ongoing dialogue with the FDA. Continuous interaction ensures that any uncertainties are addressed early on. It builds collaboration rather than competition. This back-and-forth can lead to more thorough submissions, ultimately benefiting patient safety. Think of it as a trusted partnership aiming for the same goal. Additionally, this interaction can provide invaluable insights into regulatory expectations, enabling companies to tailor their submissions more effectively and reduce the likelihood of delays caused by misunderstandings or miscommunications.

    Enhanced Risk Management

    Moreover, the Modular PMA Submission approach allows for enhanced risk management. By breaking down the submission into manageable modules, companies can identify and mitigate potential risks at each process stage. This proactive approach not only safeguards the integrity of the product but also instills confidence among stakeholders, including investors and healthcare providers. It’s akin to building a house one brick at a time, ensuring that each layer is solid before moving on to the next.

    Cost-Effectiveness

    Finally, the Modular PMA Submission can be more cost-effective in the long run. By streamlining the submission process and reducing the time to market, companies can save on development costs and allocate resources more efficiently. This financial advantage can be particularly crucial for smaller companies or startups that may not have the same level of funding as larger corporations. With the ability to bring innovations to market more quickly, these companies can also gain a competitive edge, positioning themselves as leaders in their respective fields.

    Challenges in a Modular PMA Submission

    Of course, it’s not all roses. This modular approach is not without its challenges, and companies must be keenly aware of potential pitfalls.

    Managing the Modular Process

    One challenge involves managing multiple modules. Keeping track of each component can be a juggling act. It requires a diligent approach to documentation and data management. If one module falls behind, progress on the entire submission can be delayed. It’s essential to stay organized and focused. This often means implementing project management tools and strategies to monitor timelines and responsibilities effectively. Regular team meetings can also help ensure that everyone is on the same page and that any issues are addressed promptly. The complexity of coordinating various teams-research and development, regulatory affairs, and quality assurance-adds another layer of difficulty, necessitating clear communication and collaboration.

    Ensuring Module Completeness

    Additionally, ensuring the completeness of each module is paramount. Submitting an incomplete module can lead to delays or even denials. It’s crucial to revisit and double-check every detail. Having a checklist can be invaluable in this regard. A stitch in time saves nine!

    The regulatory landscape continually evolves, so what was considered complete a year ago may no longer meet current standards. Companies must stay updated on the latest guidelines and incorporate any changes into their submissions. Engaging with regulatory consultants or attending industry workshops can provide valuable insights and help navigate these complexities. Furthermore, the review process can be lengthy, and any oversight may result in significant setbacks, emphasizing the importance of thoroughness in every module submitted.

    Tips for a Successful Modular PMA Submission

    So, how can manufacturers ensure the success of their Modular PMA Submission? By following a few key strategies, businesses can avoid common mistakes and streamline their approval process.

    Planning and Organization

    First and foremost, planning and organization are essential. Having a clear outline for each module helps tremendously. Set realistic deadlines and allocate resources wisely. A well-organized submission process makes reviewing far less daunting. Consider creating a project management timeline with milestones for each submission phase. This keeps the team on track and allows for adjustments as needed, ensuring that no critical elements are overlooked. Regular team meetings can enhance collaboration and ensure everyone is aligned on goals and responsibilities.

    Communication with FDA

    Effective communication is also crucial. Establishing rapport with FDA reviewers can facilitate smoother interactions and build understanding. Regular check-ins can keep the process transparent. After all, communication is the lifeblood of any relationship. Preparing for these interactions is beneficial by having a list of questions or concerns ready, which can help clarify any uncertainties early on. Furthermore, utilizing the FDA’s pre-submission process can provide invaluable feedback on your proposed submission strategy, allowing you to address potential issues before they arise.

    Quality Control and Assurance

    Lastly, quality control and assurance processes cannot be overlooked. It’s crucial to ensure that all data submitted is accurate and reliable. Conduct internal audits and gather feedback before submission to catch any discrepancies early. Remember, an ounce of prevention is worth a pound of cure. A standardized checklist for each module can help maintain consistency and ensure all necessary documentation is included. Additionally, training team members on best practices for data management and submission protocols can further enhance the quality of the submission, reducing the likelihood of delays due to incomplete or incorrect information.

    Consider using technology to support your quality assurance efforts. Software tools that specialize in regulatory compliance can streamline data collection and reporting, making it easier to track changes and maintain version control. This not only enhances the submission’s accuracy but also provides a clear audit trail that can be beneficial during the review process.

    Conclusion

    A Modular PMA Submission offers a unique and efficient pathway for medical device manufacturers. By understanding its components, benefits, and challenges, companies can confidently navigate the regulatory landscape. With a little planning and organization, success is within reach-like a finish line waiting to be crossed.

    As you approach the finish line of your Modular PMA Submission, remember that cybersecurity is a critical component that cannot be overlooked. Blue Goat Cyber specializes in medical device cybersecurity, ensuring that your submission meets the highest standards for FDA clearance. Our expert team, with top certifications and Veteran-Owned business status, is committed to integrating security throughout your device’s lifecycle. From advanced penetration testing to ongoing support, we tailor our services to your needs, offering fixed-fee pricing and unlimited retesting for full transparency and assurance. Don’t let cybersecurity challenges slow down your progress. Contact us today for cybersecurity help. Let us secure your devices, ensure compliance, and provide the peace of mind you need to succeed in the digital healthcare landscape.

    How Blue Goat approaches this

    Blue Goat Cyber assists medical device manufacturers in preparing and navigating each module of a Modular PMA Submission, with a particular focus on the cybersecurity aspects. Our team, composed of cybersecurity experts with CISSP and OSCP certifications and ex-military red team experience, helps structure cybersecurity documentation to meet current FDA expectations.

    We provide targeted guidance on risk management, threat modeling, and control implementation, aligning with the iterative nature of modular submissions. Our methodology ensures that each cybersecurity module is defensible and aligns with regulatory requirements. We collaborate closely with your team to integrate security across development phases, addressing potential deficiencies proactively.

    Our service offerings, such as Medical Device Penetration Testing, bolster the evidence presented in cybersecurity modules. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. This focused approach ensures efficient progress towards market approval.

    FAQ

    What is a Modular PMA Submission?

    A Modular PMA Submission is an FDA application method where manufacturers submit medical device approval information in discrete, structured modules like preclinical, manufacturing, and clinical data, rather than one large document.

    What are the benefits of a Modular PMA?

    Key benefits include increased flexibility, continuous communication and feedback from the FDA, enhanced risk management by addressing issues early, and improved efficiency in resource allocation.

    Does a Modular PMA replace traditional PMA submissions?

    No, a Modular PMA is an alternative method for submitting a Premarket Approval application. It offers a different structural approach but serves the same purpose of seeking FDA clearance for high-risk medical devices.

    What components are in a Modular PMA Submission?

    Typical components include a Preclinical Module with non-clinical data, a Manufacturing Module detailing production and quality control, and a Clinical Module presenting human study data and patient outcomes.

    How does the FDA review Modular PMA submissions?

    The FDA reviews each module as it is submitted, allowing for back-and-forth communication and potential adjustments before the entire application is complete. This iterative process allows for early identification and resolution of potential issues.

    Is a Modular PMA suitable for all medical devices?

    The suitability of a Modular PMA depends on the device's complexity and the manufacturer's development and data generation timeline. It is particularly advantageous for complex devices requiring extensive data that become available incrementally.

    Related: Medical Device Cybersecurity: A Complete Lifecycle Guide

    About the author

    Christian Espinosa, Founder & CEO at Blue Goat Cyber

    Christian Espinosa, MBA, CISSP · Founder & CEO, Blue Goat Cyber

    U.S. Air Force Academy graduate and veteran with 30+ years in cybersecurity. Founded Alpine Security in 2014 (acquired 2020), then Blue Goat Cyber in 2022. Has supported 250+ FDA medical device submissions; no client has failed to clear due to cybersecurity. Author of three books including The Smartest Person in the Room. Ironman triathlete and mountaineer.

    Read more about ChristianLinkedIn

    Sources & references

    Primary sources cited in this article. Links open in a new tab.

    1. FDA- U.S. FDA
    2. Modular PMA Submission- U.S. FDA
    More in this category

    More FDA articles

    Browse all
    Related 524B & eSTAR resources

    Keep going: the 524B and eSTAR working set

    Start with the walkthrough hub, then drill into the statute, the eSTAR field map, SBOM monitoring, postmarket planning, and deficiency response. Use these as the playbook behind every cyber device submission.

    Hub
    FDA Section 524B & eSTAR Cybersecurity Walkthrough

    Start here: the hub that ties the statute, the February 2026 guidance, and the eSTAR fields together in the order a submission team works through them.

    Related services

    Put this into practice on your device

    Every Blue Goat Cyber engagement maps directly to FDA Section 524B and the SPDF - so the evidence you need lands in your submission, not in a separate report.

    Ready when you are

    Get FDA cleared without the cybersecurity headaches.

    30-minute strategy session. No cost, no commitment - just answers from people who've shipped 250+ FDA submissions.